Advertisement
U.S. markets close in 2 hours 39 minutes
Advertisement

Geron Corporation (GERN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Visitors trend2W10W9M
1.9450+0.0850 (+4.57%)
As of 01:19PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Performance Outlook
Previous Close1.8600
Open1.8600
Bid1.9400 x 3200
Ask1.9500 x 3000
Day's Range1.8350 - 1.9550
52 Week Range1.6800 - 3.8400
Volume1,880,017
Avg. Volume5,532,733
Market Cap1.056B
Beta (5Y Monthly)0.79
PE Ratio (TTM)N/A
EPS (TTM)-0.3400
Earnings DateNov 02, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for GERN

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Geron Corporation
    Analyst Report: Exelixis, Inc.Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
    Rating
    Fair Value
    Economic Moat
    18 hours agoMorningstar
View more
  • Business Wire

    Geron Announces Publication in The Lancet of Results from the IMerge Phase 3 Clinical Trial Evaluating Imetelstat in Lower Risk MDS

    FOSTER CITY, Calif., December 04, 2023--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced publication in The Lancet of results from the IMerge Phase 3 trial investigating imetelstat versus placebo in patients with lower risk myelodysplastic syndromes (MDS) relapsed/refractory or ineligible for erythropoiesis stimulating agents (ESAs). The publication is available online and will be available in print at a later date.

  • Business Wire

    Geron Corporation Announces Appointment of Gaurav Aggarwal, M.D., to its Board of Directors

    FOSTER CITY, Calif., November 28, 2023--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced the appointment of Gaurav Aggarwal, M.D., to the Company’s Board of Directors. Dr. Aggarwal has been a prominent investor in the life sciences sector for more than two decades and has a history of expertise in financial and corporate strategy, as well as business development, in companies with which he has been affiliated at both an operational and board leve

  • Business Wire

    Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    FOSTER CITY, Calif., November 16, 2023--Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today reported that it has granted non-statutory stock options to purchase an aggregate of 438,950 shares of Geron common stock as inducements to newly hired employees in connection with commencement of employment with the Company.